240 related articles for article (PubMed ID: 11318077)
1. Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials.
Fogarty CM; Greenberg RN; Dunbar L; Player R; Marrie TJ; Kojak CM; Morgan N; Williams RR
Clin Ther; 2001 Mar; 23(3):425-39. PubMed ID: 11318077
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Jones RN; Fritsche TR; Sader HS
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
[TBL] [Abstract][Full Text] [Related]
3. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.
Heffelfinger JD; Dowell SF; Jorgensen JH; Klugman KP; Mabry LR; Musher DM; Plouffe JF; Rakowsky A; Schuchat A; Whitney CG
Arch Intern Med; 2000 May; 160(10):1399-408. PubMed ID: 10826451
[TBL] [Abstract][Full Text] [Related]
4. Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia.
Endimiani A; Brigante G; Bettaccini AA; Luzzaro F; Grossi P; Toniolo AQ
BMC Infect Dis; 2005 Nov; 5():106. PubMed ID: 16307682
[TBL] [Abstract][Full Text] [Related]
5. [Failure of levofloxacin therapy in two cases of community-acquired pneumonia caused by fluoroquinolone-resistant Streptococcus pneumoniae and complicated with empyema].
Carlavilla AB; López-Medrano F; Chaves F; Villena V; Echave-Sustaeta J; Aguado JM
Enferm Infecc Microbiol Clin; 2005 May; 23(5):270-3. PubMed ID: 15899177
[TBL] [Abstract][Full Text] [Related]
6. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia.
Anderson KB; Tan JS; File TM; DiPersio JR; Willey BM; Low DE
Clin Infect Dis; 2003 Aug; 37(3):376-81. PubMed ID: 12884162
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones.
Carratalá J; Martín-Herrero JE; Mykietiuk A; García-Rey C
Clin Microbiol Infect; 2006 May; 12 Suppl 3():2-11. PubMed ID: 16669924
[TBL] [Abstract][Full Text] [Related]
8. Risk Factors for Community-Onset Pneumonia Caused by Levofloxacin-Nonsusceptible Streptococcus pneumoniae.
Seok H; Kang CI; Huh K; Cho SY; Ha YE; Chung DR; Peck KR
Microb Drug Resist; 2018 Nov; 24(9):1412-1416. PubMed ID: 29565225
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection.
Yanagihara K; Izumikawa K; Higa F; Tateyama M; Tokimatsu I; Hiramatsu K; Fujita J; Kadota J; Kohno S
Intern Med; 2009; 48(7):527-35. PubMed ID: 19336954
[TBL] [Abstract][Full Text] [Related]
10. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
Jones RN; Sader HS; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
[TBL] [Abstract][Full Text] [Related]
11. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.
Lode H; File TM; Mandell L; Ball P; Pypstra R; Thomas M;
Clin Ther; 2002 Nov; 24(11):1915-36. PubMed ID: 12501883
[TBL] [Abstract][Full Text] [Related]
12. Levofloxacin for the treatment of pneumonia caused by Streptococcus pneumoniae including multidrug-resistant strains: pooled analysis.
Peterson J; Yektashenas B; Fisher AC
Curr Med Res Opin; 2009 Mar; 25(3):559-68. PubMed ID: 19196225
[TBL] [Abstract][Full Text] [Related]
13. Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae: nested cohort within a multicenter clinical trial.
Fujita J; Niki Y; Kadota J; Yanagihara K; Kaku M; Watanabe A; Aoki N; Hori S; Tanigawara Y; Cash HL; Kohno S
J Infect Chemother; 2013 Jun; 19(3):472-9. PubMed ID: 23179958
[TBL] [Abstract][Full Text] [Related]
14. [Levofloxacin in the treatment of community-acquired pneumococcal pneumonia].
Léophonte P; Veyssier P
Presse Med; 1999 Nov; 28(36):1975-9. PubMed ID: 10599260
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
File TM; Segreti J; Dunbar L; Player R; Kohler R; Williams RR; Kojak C; Rubin A
Antimicrob Agents Chemother; 1997 Sep; 41(9):1965-72. PubMed ID: 9303395
[TBL] [Abstract][Full Text] [Related]
16. Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia.
Kays MB; Smith DW; Wack ME; Denys GA
Pharmacotherapy; 2002 Mar; 22(3):395-9. PubMed ID: 11898897
[TBL] [Abstract][Full Text] [Related]
17. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
Martin SJ; Jung R; Garvin CG
Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
[TBL] [Abstract][Full Text] [Related]
18. Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections.
Casellas JM; Gilardoni M; Tome G; Goldberg M; Ivanovic S; Orduna M; Dolmann A; Ascoli M; Ariza H; Montero JM
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():37-42. PubMed ID: 10404336
[TBL] [Abstract][Full Text] [Related]
19. Drug-resistance in Streptococcus pneumoniae isolates among Spanish middle aged and older adults with community-acquired pneumonia.
Vila-Corcoles A; Bejarano-Romero F; Salsench E; Ochoa-Gondar O; de Diego C; Gomez-Bertomeu F; Raga-Luria X; Cliville-Guasch X; Arija V
BMC Infect Dis; 2009 Mar; 9():36. PubMed ID: 19320989
[TBL] [Abstract][Full Text] [Related]
20. Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study.
von Gottberg A; Klugman KP; Cohen C; Wolter N; de Gouveia L; du Plessis M; Mpembe R; Quan V; Whitelaw A; Hoffmann R; Govender N; Meiring S; Smith AM; Schrag S;
Lancet; 2008 Mar; 371(9618):1108-13. PubMed ID: 18359074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
